Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

13645results about "Fusion polypeptide" patented technology

Muscle targeting complexes and uses thereof for treating dystrophinopathies

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.
Owner:DYNE THERAPEUTICS INC

Muscle targeting complexes and uses thereof for treating dystrophinopathies

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.
Owner:DYNE THERAPEUTICS INC

Muscle targeting complexes and uses thereof for treating dystrophinopathies

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.
Owner:DYNE THERAPEUTICS INC

GLP-1R and GCGR double-target-activated polypeptide or derivative thereof, pharmaceutically acceptable salt and application of polypeptide or derivative and pharmaceutically acceptable salt

The invention provides a polypeptide or a derivative and a pharmaceutically acceptable salt thereof. The amino acid sequence of the polypeptide is as shown in SEQ ID NO: 1. The polypeptide or the derivative and the pharmaceutically acceptable salt thereof disclosed by the invention can be combined with GLP-1R and GCGR, and is used for effectively activating the GLP-1R and the GCGR. Therefore, the polypeptide or the derivative and the pharmaceutically acceptable salt thereof can be used for detecting GLP-1R and / or GCGR, and can also be used for treating or preventing GLP-1R and / or GCGR related diseases (such as metabolic disorder related diseases, such as obesity, diabetes, fatty liver diseases, non-alcoholic fatty liver diseases and the like).
Owner:TENCENT TECHNOLOGY (SHENZHEN) CO LTD

Nanobody Targeting Human Serum Albumin and Its Application

The present invention discloses a human serum albumin-targeting nanobody and its application. A variety of human serum albumin-targeting nanobodies that can be used to construct long-acting fusion protein drugs and their immune screening methods are disclosed. The antibody is composed only of the heavy chain variable region and can be fused and expressed with therapeutic proteins or polypeptide drugs such as interleukin, interferon, and tumor necrosis factor in an Escherichia coli expression system. The fusion protein has the activity of specifically binding to human serum albumin, has a relatively high affinity, can effectively extend the drug half-life, and does not affect the biological activity of the recombinant protein drug at the same time.
Owner:CHANGCHUN INST OF BIOLOGICAL PRODS

Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of a DMPK allele comprising a disease-associated-repeat. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
Owner:DYNE THERAPEUTICS INC

Polypeptide modification method for purifying polypeptide multimers

The present invention provides efficient methods based on alteration of the protein A-binding ability, for producing or purifying multispecific antibodies having the activity of binding to two or more types of antigens to high purity through a protein A-based purification step alone. The methods of the present invention for producing or purifying multispecific antibodies which feature altering amino acid residues of antibody heavy chain constant region and / or variable region. Multispecific antibodies with an altered protein A-binding ability, which exhibit plasma retention comparable or longer than that of human IgG1, can be efficiently prepared in high purity by introducing amino acid alterations of the present invention into antibodies.
Owner:CHUGAI PHARMA CO LTD

Methods and compositions for editing nucleotide sequences

The present disclosure provides new prime editor guide RNAs for prime editing, constructs for prime editing, and methods for using same. In addition, the present disclosure provides compositions and methods for conducting prime editing of a target DNA molecule (e.g., a genome) that enables the incorporation of a nucleotide change and / or targeted mutagenesis (e.g., insertion or deletion). The nucleotide change can include a single-nucleotide change (e.g., any transition or any transversion), an insertion of one or more nucleotides, or a deletion of one or more nucleotides. More in particular, the disclosure provides fusion proteins comprising nucleic acid programmable DNA binding proteins (napDNAbp) and a polymerase (e.g., reverse transcriptase), which is guided to a specific DNA sequence by a prime editor RNA (PEgRNA). The prime editor guide RNA comprises an extension arm that provides a DNA synthesis template sequence which encodes a single strand DNA flap, which is homologous to an endogenous DNA sequence, but which contains the desired one or more nucleotide changes and which, following synthesis by the polymerase (e.g., reverse transcriptase), becomes incorporated into the target DNA molecule.
Owner:HOWARD HUGHES MEDICAL INST +2

Novel type of crispr / cas system

The technology described herein relates to new CRISPR / Cas systems and components thereof, vectors, proteins, fusion proteins, ribonucleoprotein complexes and methods of using the new system and components. The new system can be used in CRISPRi applications and can be fused to any number of effector domain modalities, such as nucleases, base editors, prime editors and the like to perform various DNA modifications.
Owner:SNIPR BIOME APS

Recombinant human III-type collagen with triple-helix structure and assembled into collagenous fiber and application of recombinant human III-type collagen

The invention provides recombinant human III-type collagen which is of a triple-helix structure and assembled into collagenous fibers and application of the recombinant human III-type collagen, and belongs to the technical field of bioengineering. Collagen fragments capable of forming a triple helix structure are screened out through a bioinformatics algorithm, the fragments are connected in series, a key C-terminal structural domain and a specific amino acid sequence are combined, and formation of a stable triple helix advanced structure and assembly of collagenous fibers are effectively promoted. The recombinant human III type collagen is efficiently expressed through a eukaryotic expression system, and shows excellent stability, low immunogenicity and good biocompatibility. Experimental results show that the prepared recombinant human III-type collagen not only has a natural triple helix structure, but also can be further assembled into macromolecular collagen fibers, is suitable for multiple fields such as medical beauty, bioengineering and tissue repair, and has wide application prospects and market values.
Owner:CHANGCHUN PUMAIFU BIOTECHNOLOGY CO LTD

An improved process for purification of fusion protein

The present invention relates to purification process of pharmacologically active cytotoxic T lymphocyte-associated 4-immunoglobulin (CTLA4-lg) fusion protein by using three column chromatography steps that provides purified form of the fusion protein, substantially free of misfolded species, charge variants and aggregates. A method for purifying a fusion protein from a protein mixture comprising a fusion protein and high molecular weight (HMW) impurity.
Owner:ACQUIOM AGENCY SERVICES LLC AS COLLATERAL AGENT

Recombinant humanized XVII type collagen as well as expression vector and genetically engineered bacterium thereof

The invention discloses a recombinant humanized XVII type collagen as well as an expression vector and a genetically engineered bacterium thereof. Four functional fragments with high activity are obtained through screening, one of the fragments is optimized and then combined according to a certain sequence to obtain recombinant humanized XVII type collagen JYC1703, or one of the fragments is optimized and then combined according to a certain sequence, and GPP sequences are fused at an amino terminal and a carboxyl terminal respectively to obtain recombinant humanized XVII type collagen JYC1701 and JYC1702, and the recombinant humanized XVII type collagen JYC1701 and JYC1702 are combined according to a certain sequence to obtain the recombinant humanized XVII type collagen JYC1701 and JYC1702. After codon optimization, amplifying and cloning into an expression vector, transforming into pichia pastoris competent cells after enzyme digestion linearization, and screening high-copy recombinants through G418 resistance gradient, so as to obtain pichia pastoris genetically engineered bacteria for expressing recombinant humanized XVII type collagen. The recombinant humanized XVII type collagen JYC1701, JYC1702 and JYC1703 disclosed by the invention show excellent functions of promoting cell adhesion, cell proliferation and cell migration, and are suitable for preparing products such as skin care products or medical instruments and the like.
Owner:ZHEJIANG ZHUJI JUYUAN BIOTECHNOLOGY CO LTD

GLP-1R activating polypeptide or pharmaceutically acceptable salt thereof and application thereof

The invention provides a polypeptide or a pharmaceutically acceptable salt of the polypeptide. The amino acid sequence of the polypeptide is as shown in HSQGTFTSDYSKYLEEAAAAEFVAWLLAGG. The invention further provides a preparation method of the polypeptide. The polypeptide or the pharmaceutically acceptable salt thereof can be combined with the GLP-1R and is used for effectively activating the GLP-1R. Therefore, the polypeptide or the pharmaceutically acceptable salt thereof can be used for effectively treating metabolic disorder related diseases (such as obesity, diabetes, dyslipidemia related diseases, fatty liver diseases, metabolic syndromes and non-alcoholic fatty liver diseases).
Owner:TENCENT TECHNOLOGY (SHENZHEN) CO LTD

Dual cytokine fusion proteins comprising IL-10

The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and / or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.
Owner:IOVANCE BIOTHERAPEUTICS INC

Recombinant herpes zoster vaccine as well as preparation method and application thereof

ActiveCN119386170Ahigh titerstrong immune responseAntibody mimetics/scaffoldsViral antigen ingredientsHerpes zoster virusHerpes Zoster Vaccine
The invention discloses a recombinant herpes zoster vaccine as well as a preparation method and application thereof, and particularly relates to the technical field of biological medicines. The recombinant herpes zoster vaccine comprises a recombinant herpes zoster vaccine fusion protein purified product HN101 and a liposome mixture HA201, and the recombinant herpes zoster fusion protein gE-gD is constructed by recombining reconstructed gE protein and reconstructed gD protein. The gE-gD recombinant herpes zoster fusion protein is obtained by reconstructing gE protein of varicella-herpes zoster virus and gD protein of HSV through a gene recombination technology and then recombining the gE protein and the gD protein. After the gE-gD recombinant herpes zoster fusion protein is combined with a liposome mixture HA201, stronger immune response can be induced, the antibody titer and cellular immunity are improved, the vaccine effect is enhanced, and meanwhile, the potential infection risk is avoided.
Owner:JIANGSU WALVAX BIOTECHNOLOGY CO LTD

Optimized binuclease fusions and methods

The invention provides for optimized binuclease fusion proteins with increased pharmacokinetic properties. The optimized binuclease fusion proteins of the invention two or more nuclease domains (e.g., RNase and DNase domain) operably coupled to an Fc domain. The invention also provides methods of treating or preventing a condition associated with an abnormal immune response.
Owner:RESOLVE THERAPEUTICS LLC

Fusion enzyme for efficiently degrading PET (polyethylene terephthalate) plastic and application of fusion enzyme

The invention discloses a fusion enzyme capable of efficiently degrading PET (polyethylene terephthalate) plastic and application of the fusion enzyme. The invention provides a recombinant fusion enzyme. The recombinant fusion enzyme comprises a mutant KL-MHETase of thermophilic carboxylesterase Est30 and a PET (Polyethylene Terephthalate) degrading enzyme FAST-PETase, the amino acid sequence of the mutant KL-MHETase of the thermophilic carboxylesterase Est30 is as shown in SEQ ID NO. 3; the amino acid sequence of the FAST-PETase is as shown in the 284th to 546th amino acids of SEQ ID NO.1 (Sequence Identifier Number 1). The fusion enzyme is used as a biocatalyst, the activity of catalyzing hydrolysis of MHET at 50 DEG C is 52.6 times that of FAST-PETase, and the fusion enzyme has high enzyme activity and thermal stability. PET degradation is catalyzed at the temperature of 50 DEG C, the conversion rate of PET is 90% after 48 hours of reaction, and meanwhile, the TPA content in the product is close to 100%.
Owner:BEIJING UNIV OF CHEM TECH

Method for editing cattle gene based on Pro-iCHI

The invention belongs to the technical field of molecular biology and genetics, and particularly relates to a method for editing cattle genes based on Pro-iCHI. The invention provides a method for editing cattle genes based on Pro-iCHI, which comprises the following steps: transiently expressing protamine in cattle AG-haESCs after gene editing, and injecting into mature oocytes to obtain reconstructed embryos. The protamine can remove abnormal DNA methylation generated by an oocyte cytoplasm injection haploid stem cell technology, cell nucleuses are compressed into a sperm-like structure, the obtained bovine Pro-iCHI embryo can smoothly develop into a blastocyst, and the ratio of the blastocyst to the blastocyst obtained by in-vitro fertilization is equivalent. Moreover, the protamine coding gene is inserted into the saccharomyces cerevisiae protein expression vector and then is subjected to transient expression, so that the protamine coding gene cannot be integrated into a genome to cause insertion of an exogenous gene while abnormal DNA methylation is erased.
Owner:INNER MONGOLIA UNIVERSITY

Multifunctional molecules that bind to calreticulin and uses thereof

Multifunctional molecules that include i) an antigen binding domain that binds to a calreticulin mutant protein; and one, two or all of: (ii) an immune cell engager (e.g., chosen from an NK cell engager, a T cell engager, a B cell engager, a dendritic cell engager, or a macrophage cell engager); (iii) a cytokine molecule or a modulator of a cytokine molecule; and / or (iv) a stromal modifying moiety are disclosed. Additionally disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.
Owner:MARENGO THERAPEUTICS INC

Genetically engineered algae capable of resisting aquatic pathogenic bacteria as well as construction method and application of genetically engineered algae

The invention discloses a genetically engineered algae capable of resisting aquatic pathogenic bacteria as well as a construction method and application thereof, and is characterized in that the genetically engineered algae is phaeodactylum tricornutum into which cell wall energizing plasmids pPha-T1-J48054-eGFP-Linker-Q4 or pPha-T1-J48054-eGFP-Linker-Q6 are introduced, and the preparation method of the genetically engineered algae comprises the following steps: taking genome DNA of the phaeodactylum tricornutum as a template; the method comprises the following steps: constructing a directional expression plasmid pPha-T1-J48054-eGFP by amplifying a Phatr3J48054 coding sequence, inserting Q4 and Q6 coding sequences into the downstream of the eGFP of a directional expression vector, constructing a cell wall energizing plasmid, electrically transforming the cell wall energizing plasmid into phaeodactylum tricornutum, coating an f / 2 plate culture medium with transformed phaeodactylum tricornutum cells for culturing, screening positive algae strains, and screening the positive algae strains. The feed additive has the advantage of inhibiting or killing aquatic pathogenic bacteria.
Owner:NINGBO UNIV

Nk / monocyte engagers

This invention provides a tetrahedral antibody comprising a first, second, third, fourth, fifth, and sixth domain, wherein each of the first and second domains are an Fc domain of an IgG antibody comprising S239D and I332E mutations on both the first polypeptide chain and second polypeptide chain of the domain; the third domain and fourth domains are each a Fab domain comprising the V region of a Fab domain of FMC59 or a variant thereof with at least 95% identity to said V region; and the fifth and sixth domains are each a Fab domain comprising the V region of a Fab domain of Rituximab or a variant thereof with at least 95% identity to said V region.
Owner:BIOMOLECULAR HOLDINGS LLC

Use of recombinant expressed protein in prevention and / or treatment of respiratory disease

A use of a recombinant expressed protein in prevention and / or treatment of a respiratory disease. Provided is a use of two recombinant expressed proteins in preparation of a drug for prevention and / or treatment of a respiratory disease. The respiratory disease is caused by influenza A virus infection or co-infection of influenza A virus and novel coronavirus. GRFT has an amino acid sequence shown in SEQ ID NO: 1, and GL25E has an amino acid sequence shown in SEQ ID NO: 2. The recombinant protein GRFT and fusion protein GL25E can effectively inhibit the influenza A virus infection, wherein GL25E is formed by coupling an EK1 polypeptide on the basis of GRFT, the recombinant protein GRFT and fusion protein GL25E have good inhibitory activity against influenza A virus, also have good inhibitory activity against the co-infection of influenza virus and novel coronavirus, and can be used in preparation of drugs for prevention and / or treatment of respiratory diseases caused by influenza virus and the co-infection of influenza virus and coronavirus.
Owner:SHANXI JINBO BIO PHARMACEUTICAL CO LTD +1

Increased production of acetyl-phosphate and products derived therefrom in yeasts

PCT designated stage expiredWO2025133860A1Antibody mimetics/scaffoldsHydrolases
The present disclosure concerns a fusion polypeptide for making acetyl-phosphate from glucose, a recombinant yeast host cell expressing the fusion polypeptide as well as methods of using the fusion polypeptide. The fusion polypeptide comprising (i) a glucose-6-phosphate isomerase moiety and (ii) a phosphoketolase moiety.
Owner:DANSTAR FERMENT AG

Combination containing an mRNA vaccine or an mRNA encoded therapeutic protein and an immune modulating mRNA for improved or reduced immunogenicity to increase efficacy

The present invention pertains to a combination comprising two or more mRNA molecules, or a single mRNA molecule encoding a first molecule, which is a therapeutic or immunogenic protein or peptide, and a second molecule, which is a protein or a peptide having the ability to modulate an immune response against the first molecule and / or the translation product of the first molecule, wherein the combination comprises at least one first mRNA molecule encoding a first molecule, which is a therapeutic or immunogenic protein or peptide, and at least one second mRNA molecule encoding a second molecule, which is a protein or a peptide having the ability to modulate an immune response against the first molecule and / or the translation product of the first molecule. The invention also relates to a host cell comprising a combination or the single mRNA molecule according to the present invention, a pharmaceutical composition comprising the combination, the single mRNA molecule, or the host cell of the present invention, and a vaccine comprising the combination, the single mRNA molecule, the host cell, or the pharmaceutical composition according to the present invention. Further provided is a kit comprising the combination, the single mRNA molecule, the host cell, the pharmaceutical composition, or the vaccine according to the present invention. The invention also pertains to the combination, the single mRNA molecule, the host cell, the pharmaceutical composition, the vaccine, or the kit according to the present invention, for use in medicine. Finally, the invention also relates to the combination, the single mRNA molecule, the host cell, the pharmaceutical composition, the vaccine, or the kit according to the present invention, for use in a method of prevention, and / or treatment of an infectious, a genetic, or a proliferative disease.
Owner:IMGEN-T-SRL

Adenosine nucleobase editors and uses thereof

The disclosure provides adenosine deaminases that are capable of deaminating adenosine in DNA. The disclosure also provides fusion proteins comprising a Cas9 (e.g., a Cas9 nickase) domain and adenosine deaminases that deaminate adenosine in DNA. In some embodiments, the fusion proteins further comprise a nuclear localization sequence (NLS), and / or an inhibitor of base repair, such as, a nuclease dead inosine specific nuclease (dISN).
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Fusion protein and preparation method thereof, cosmetic and medicine

The invention provides a fusion protein and a preparation method thereof, cosmetics and drugs, amino acid sequences of the fusion protein comprise amino acid sequences of 483-512 fragments and amino acid sequences of 1232-1466 fragments of a human III type collagen chain alpha-1 chain, and the amino acid sequences are connected by using linkers; the fusion protein has the advantages of small molecular weight, simple synthesis, convenient prokaryotic expression production, and easy large-scale production. And the fusion protein has a remarkable effect of promoting cell adhesion, is high in temperature stability and high in acting efficiency, and can meet commercial application.
Owner:GUANGZHOU LINGTIDE BIOTECHNOLOGY CO LTD

Methods of using activin receptor type ii variants

PCT designated stage expiredWO2024238950A1Antibody mimetics/scaffoldsPeptide/protein ingredientsActivin Receptors Type IIRenal transplant
The invention features methods for the treatment of Alport syndrome using a polypeptide containing an extracellular ActRII variant, such as a polypeptide containing an extracellular ActRII chimera or an extracellular ActRIIB variant. The polypeptide may include an extracellular ActRII chimera or an extracellular ActRIIB variant fused to an Fc domain monomer. Treatment of Alport syndrome with a polypeptide described herein may reduce kidney inflammation, reduce kidney fibrosis, slow disease progression, and / or improve kidney function, which may reduce or delay the need for a kidney transplant or dialysis.
Owner:KEROS THERAPEUTICS INC

Drug delivery carrier based on extracellular vesicles and application thereof

The invention relates to a drug delivery carrier based on extracellular vesicles and application thereof.The drug delivery carrier contains extracellular vesicle scaffold protein and recombinant membrane fusion protein, the recombinant membrane fusion protein comprises a first fragment and a second fragment, the amino acid sequence of the first fragment is shown as SEQ ID NO: 5, and the amino acid sequence of the second fragment is shown as SEQ ID NO: 6; the second fragment has n amino acids, the sequence of the second fragment is the sequence of the first n amino acids at the N end of the amino acid sequence as shown in SEQ ID NO: 7, and n is an integer between 50 and 200. According to the drug delivery carrier disclosed by the invention, the efficiency of releasing drug active molecules before reaching lysosome is remarkably improved, and the drug effect of extracellular vesicle drugs can be improved.
Owner:苏州唯思尔康科技有限公司